image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 7.21
-2.3 %
$ 3.36 B
Market Cap
-18.97
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMRX stock under the worst case scenario is HIDDEN Compared to the current market price of 7.21 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMRX stock under the base case scenario is HIDDEN Compared to the current market price of 7.21 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AMRX stock under the best case scenario is HIDDEN Compared to the current market price of 7.21 USD, Amneal Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMRX

image
$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.79 B REVENUE
16.73%
249 M OPERATING INCOME
21.99%
-73.9 M NET INCOME
-51.63%
295 M OPERATING CASH FLOW
-14.61%
-63 M INVESTING CASH FLOW
8.95%
-212 M FINANCING CASH FLOW
0.37%
731 M REVENUE
3.99%
75.8 M OPERATING INCOME
-14.66%
-20.7 M NET INCOME
-176.42%
118 M OPERATING CASH FLOW
-16.71%
-16.1 M INVESTING CASH FLOW
22.47%
-61.2 M FINANCING CASH FLOW
33.72%
Balance Sheet Amneal Pharmaceuticals, Inc.
image
Current Assets 1.59 B
Cash & Short-Term Investments 111 M
Receivables 776 M
Other Current Assets 702 M
Non-Current Assets 1.91 B
Long-Term Investments 0
PP&E 524 M
Other Non-Current Assets 1.39 B
3.16 %22.15 %20.04 %14.96 %39.70 %Total Assets$3.5b
Current Liabilities 1.13 B
Accounts Payable 259 M
Short-Term Debt 240 M
Other Current Liabilities 631 M
Non-Current Liabilities 1.29 B
Long-Term Debt 91.1 M
Other Non-Current Liabilities 1.2 B
10.71 %9.94 %26.11 %3.77 %49.47 %Total Liabilities$2.4b
EFFICIENCY
Earnings Waterfall Amneal Pharmaceuticals, Inc.
image
Revenue 2.79 B
Cost Of Revenue 1.77 B
Gross Profit 1.02 B
Operating Expenses 771 M
Operating Income 249 M
Other Expenses 323 M
Net Income -73.9 M
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)3b(2b)1b(771m)249m(323m)(74m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
36.52% GROSS MARGIN
36.52%
8.92% OPERATING MARGIN
8.92%
-4.18% NET MARGIN
-4.18%
106.97% ROE
106.97%
-3.34% ROA
-3.34%
12.82% ROIC
12.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amneal Pharmaceuticals, Inc.
image
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -73.9 M
Depreciation & Amortization 236 M
Capital Expenditures -51.9 M
Stock-Based Compensation 27.8 M
Change in Working Capital 0
Others 105 M
Free Cash Flow 243 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amneal Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AMRX of $10.6 , with forecasts ranging from a low of $9 to a high of $12 .
AMRX Lowest Price Target Wall Street Target
9 USD 24.83%
AMRX Average Price Target Wall Street Target
10.6 USD 47.02%
AMRX Highest Price Target Wall Street Target
12 USD 66.44%
Price
Max Price Target
Min Price Target
Average Price Target
1212111110109988776655May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Amneal Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
47.3 M USD 6
3-6 MONTHS
1.61 M USD 4
6-9 MONTHS
1.27 M USD 2
9-12 MONTHS
256 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU™ (bortezomib injection), a pr. businesswire.com - 2 weeks ago
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. seekingalpha.com - 1 month ago
Amneal to Participate at Upcoming Investor Conference BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference. businesswire.com - 1 month ago
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA. businesswire.com - 1 month ago
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Balaji Prasad - Barclays Operator Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 Earnings Call. seekingalpha.com - 1 month ago
Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago. zacks.com - 1 month ago
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results. businesswire.com - 1 month ago
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 month ago
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock? Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio. benzinga.com - 1 month ago
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
8. Profile Summary

Amneal Pharmaceuticals, Inc. AMRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 3.36 B
Dividend Yield 0.00%
Description Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Contact 400 Crossing Boulevard, Bridgewater, NJ, 08807 https://www.amneal.com
IPO Date May 7, 2018
Employees 8300
Officers Dr. Sanjay Kumar Jain Ph.D. Chief Quality Officer Mr. Chirag K. Patel Co-Founder, Co-Chief Executive Officer, President & Director Ms. Nikita Shah Executive Vice President & Chief Human Resources Officer Mr. Anthony DiMeo Head of Investor Relations Mr. Gregory Sgammato Senior Vice President of Corporate Development Mr. Pranav Mehta Senior Vice President of Strategic Sourcing & Supply Management Mr. Chintu Patel R.Ph. Co-Founder, Co-Chief Executive Officer & Director Mr. Anastasios G. Konidaris Executive Vice President & Chief Financial Officer Mr. Jason B. Daly Esq. Executive Vice President, Chief Legal Officer & Corporate Secretary Mr. Andrew S. Boyer Executive Vice President and Chief Commercial Officer of Generics & Biosciences